Tech Transfer eNews Blog
University-Industry Engagement Advisor

Thomas Jefferson U licenses cancer vaccine technology to BioVaxys

By Jesse Schwartz
Published: July 11th, 2018

Thomas Jefferson University (TJU) in Philadelphia and biotech company BioVaxys have entered into an exclusive worldwide license agreement to commercialize immunotherapeutic vaccines for the treatment of ovarian cancer, melanoma, and other solid tumor types.

“Jefferson is extremely excited about the merging of this potentially lifesaving technology with the excellent team of scientists and business leaders at BioVaxys,” says Rose Ritts, executive vice president and chief innovation officer at TJU.

BioVxys previously carried out successful studies of its vaccine at TJU. Under the new license agreement, the company will co-develop its technology with an immunomodulating drug to increase efficacy.

“This effort will greatly increase the commercial value of the BioVaxys approach and potentially lead to the development and marketing of purified antigen vaccines, which is further justification of our interest,” says James Passin, co-founder of BioVaxys and director of the New York-based Firebird Global Master Fund, which is an early backer of the company. BioVaxys plans to submit an IND for a Phase I/II study in the upcoming months.

Source: Business Wire

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment